These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 12094858

  • 1. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
    Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ, Binion DG.
    Am J Gastroenterol; 2002 Jun; 97(6):1408-14. PubMed ID: 12094858
    [Abstract] [Full Text] [Related]

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 3. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [Abstract] [Full Text] [Related]

  • 4. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

  • 5. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ, Hanauer SB.
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [Abstract] [Full Text] [Related]

  • 6. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN.
    Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944
    [Abstract] [Full Text] [Related]

  • 7. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS, Markowitz J, Wyllie R.
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [Abstract] [Full Text] [Related]

  • 8. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 9. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 10. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):851-8. PubMed ID: 16918890
    [Abstract] [Full Text] [Related]

  • 11. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 01; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 12. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.
    Aliment Pharmacol Ther; 2008 Jul 01; 28(2):221-7. PubMed ID: 18485127
    [Abstract] [Full Text] [Related]

  • 13. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P, Belgian Group of Infliximab Expanded Access Program in Crohn's Disease.
    Am J Gastroenterol; 2002 Sep 01; 97(9):2357-63. PubMed ID: 12358256
    [Abstract] [Full Text] [Related]

  • 14. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L.
    Am J Gastroenterol; 2002 Sep 01; 97(9):2350-6. PubMed ID: 12358255
    [Abstract] [Full Text] [Related]

  • 15. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J.
    Scand J Gastroenterol; 2002 Jul 01; 37(7):818-24. PubMed ID: 12190096
    [Abstract] [Full Text] [Related]

  • 16. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
    Gheorghe L, Gheorghe C, Badea M, Vădan R, Pârvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Călin I, Diculescu M.
    Rom J Gastroenterol; 2003 Mar 01; 12(1):7-13. PubMed ID: 12673373
    [Abstract] [Full Text] [Related]

  • 17. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.
    Aliment Pharmacol Ther; 2005 Dec 01; 22(11-12):1107-13. PubMed ID: 16305724
    [Abstract] [Full Text] [Related]

  • 18. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP.
    Clin Immunol; 2006 Jan 01; 118(1):11-9. PubMed ID: 16125467
    [Abstract] [Full Text] [Related]

  • 19. Infliximab therapy in Crohn's disease: a pragmatic approach?
    Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.
    Aliment Pharmacol Ther; 2006 Jul 15; 24(2):351-9. PubMed ID: 16842462
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
    Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP.
    Gastroenterol Clin Biol; 2002 Nov 15; 26(11):973-9. PubMed ID: 12483127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.